Skip to content
Imvax
  • Contact Us
  • Privacy/Terms
  • Join Our Team
Transforming Cancer OutcomesTM
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisors
  • Technology & Proprietary Methodologies
    • Patient Cell Harvest, Treatment, and Implant
    • Immunogenic Cell Death, Patient-Specific Antigens, Innate Immune System Activation
    • Long-term Adaptive Immune Activation and Response
  • Therapeutic Areas
    • Malignant Gliomas
  • Pipeline
    • IGV-001
  • Patients
  • News & Publications
  • Collaboration and Partnerships
Imvax
Home > News & Publications > Imvax Appoints Sean Hemingway as Chief Operating Officer
  • Share
    •  
    •  
  • Print

Imvax Appoints Sean Hemingway as Chief Operating Officer

Posted April 8, 2021April 8, 2021 Vera
Press-Release_COO_Sean-Hemingway0408212

Post navigation

⟵ Imvax Abstracts Accepted for Presentation at AACR 2021 Annual Meeting
Imvax to present at UBS Global Healthcare Virtual Conference ⟶

News

Stay informed about our latest
news and developments.

LEARN MORE

Patients

Our patients are the heart of our company, and they, along with their families, friends and caregivers, are just as much members of the Imvax Team.

LEARN MORE

601 Walnut St, Suite 440 W
Philadelphia, PA 19106

tel 267-900-4110

  • About Us
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Technology & Proprietary Methodologies
  • Patient Cell Harvest, Treatment, and Implant
  • Immunogenic Cell Death, Patient-Specific Antigens, Innate Immune System Activation
  • Long-term Adaptive Immune Activation and Response
  • Pipeline
  • IGV-001
  • Therapeutic Areas
  • Malignant Gliomas
close ×
IGV-001
  • Patients
  • News & Publications
  • Collaboration and Partnerships
  • Join Our Team
Website by Axxiem
© Copyright Imvax, Inc. All Right Reserved
Privacy/Terms | Sitemap